Rothschild & Co. Asset Management US Inc. increased its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 5,793.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 620,095 shares of the biopharmaceutical company’s stock after purchasing an additional 609,574 shares during the period. Rothschild & Co. Asset Management US Inc.’s holdings in Bristol-Myers Squibb were worth $37,385,000 as of its most recent SEC filing.
Other large investors have also bought and sold shares of the company. Fiduciary Planning LLC acquired a new position in Bristol-Myers Squibb in the third quarter valued at about $25,000. Laidlaw Wealth Management LLC boosted its holdings in Bristol-Myers Squibb by 11,407.0% in the second quarter. Laidlaw Wealth Management LLC now owns 1,900,156 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 1,883,643 shares during the last quarter. JCIC Asset Management Inc. boosted its holdings in Bristol-Myers Squibb by 37.8% in the second quarter. JCIC Asset Management Inc. now owns 620 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 170 shares during the last quarter. HBC Financial Services PLLC raised its position in Bristol-Myers Squibb by 166.7% in the second quarter. HBC Financial Services PLLC now owns 800 shares of the biopharmaceutical company’s stock worth $47,000 after acquiring an additional 500 shares during the period. Finally, CVA Family Office LLC raised its position in shares of Bristol-Myers Squibb by 118.0% during the 2nd quarter. CVA Family Office LLC now owns 1,090 shares of the biopharmaceutical company’s stock valued at $64,000 after purchasing an additional 590 shares during the period. 72.61% of the stock is owned by hedge funds and other institutional investors.
NYSE BMY traded down $0.33 on Tuesday, reaching $64.17. The company had a trading volume of 203,216 shares, compared to its average volume of 13,643,771. The firm has a market capitalization of $145.94 billion, a PE ratio of -586.31, a P/E/G ratio of 1.09 and a beta of 0.67. The company has a debt-to-equity ratio of 0.82, a current ratio of 1.67 and a quick ratio of 1.58. The firm has a 50-day moving average of $73.56 and a 200-day moving average of $81.39. Bristol-Myers Squibb has a 1 year low of $45.76 and a 1 year high of $68.34.
Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Tuesday, November 10th. The biopharmaceutical company reported $1.63 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.49 by $0.14. Bristol-Myers Squibb had a positive return on equity of 27.48% and a negative net margin of 0.11%. The firm had revenue of $10.54 billion for the quarter, compared to analyst estimates of $10.33 billion. During the same period last year, the company earned $1.17 earnings per share. The firm’s revenue for the quarter was up 75.5% on a year-over-year basis. As a group, sell-side analysts expect that Bristol-Myers Squibb will post 6.34 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Monday, November 2nd. Investors of record on Friday, October 2nd were paid a $0.45 dividend. This represents a $1.80 annualized dividend and a yield of 2.81%. The ex-dividend date of this dividend was Thursday, October 1st. Bristol-Myers Squibb’s dividend payout ratio is currently 38.38%.
In related news, CEO Giovanni Caforio sold 39,840 shares of the firm’s stock in a transaction that occurred on Monday, August 31st. The stock was sold at an average price of $62.70, for a total value of $2,497,968.00. Following the transaction, the chief executive officer now directly owns 445,584 shares of the company’s stock, valued at approximately $27,938,116.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.14% of the stock is owned by company insiders.
A number of equities analysts have commented on the stock. Berenberg Bank assumed coverage on shares of Bristol-Myers Squibb in a research note on Tuesday, September 29th. They issued a “buy” rating and a $73.00 price objective for the company. Sanford C. Bernstein restated a “market perform” rating and issued a $72.00 price target on shares of Bristol-Myers Squibb in a report on Tuesday, November 10th. Morgan Stanley boosted their price objective on shares of Bristol-Myers Squibb from $64.00 to $66.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 12th. Guggenheim raised shares of Bristol-Myers Squibb from a “neutral” rating to a “buy” rating and set a $70.00 target price on the stock in a research report on Monday, October 19th. Finally, Societe Generale raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $76.00 price objective on the stock in a report on Monday. One investment analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $73.69.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products in the following therapeutic classes: hematology, oncology, cardiovascular, and immunology. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with active RA and prostate-specific antigen, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis.
Read More: Mutual Funds
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.